Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER study)
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms MASTER
- Sponsors Roche
- 22 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Feb 2011 New source identified and integrated (ClinicalTrials.gov record).
- 09 Dec 2010 New trial record